Ubiquitin proteasome inhibition and cancer therapy.
Shah
Shimul A
SA
Department of Surgery, University of Massachusetts Medical School, Worcester, USA.
Potter
Michael W
MW
Callery
Mark P
MP
D000970:Antineoplastic Agents / Q000627:therapeutic use*; D017209:Apoptosis / Q000502:physiology; D002453:Cell Cycle / Q000502:physiology; D002986:Clinical Trials as Topic; D003546:Cysteine Endopeptidases / Q000502:physiology; D019008:Drug Resistance, Neoplasm / Q000502:physiology; D006801:Humans; D009097:Multienzyme Complexes / Q000037:antagonists & inhibitors* / Q000502:physiology; D010447:Peptide Hydrolases / Q000502:physiology; D046988:Proteasome Endopeptidase Complex; D014158:Transcription, Genetic / Q000502:physiology; D025801:Ubiquitin / Q000037:antagonists & inhibitors* / Q000502:physiology
D000970:Antineoplastic Agents; D009097:Multienzyme Complexes; D025801:Ubiquitin; D010447:Peptide Hydrolases; D003546:Cysteine Endopeptidases; D046988:Proteasome Endopeptidase Complex; C061553:ATP dependent 26S protease